The NIMH-funded Schizophrenia clinical research is led by John Kane, a schizophrenia researcher and Feinstein Institutes professor. Credit: PRNewsfoto.

The National Institutes of Mental Health (NIMH) has granted $7.3m to researchers at the Feinstein Institutes for Medical Research to support their efforts to provide improved treatment for schizophrenia.

The schizophrenia clinical research study is led by Dr John Kane and Dr Delbert Robinson under the name ‘Early-phase Schizophrenia: Practice-based Research to Improve Treatment Outcomes (ESPRITO).’

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Schizophrenia is a serious mental illness and brain disabling chronic disorder that impacts a persons ability to control their emotions.

It is also defined by disorganised thinking and abnormal social behaviour, as well as disturbances in perceptions.

Feinstein Institutes Institute of Behavioral Science professor and schizophrenia researcher Dr John Kane said: “We are excited to build off of our previous work to develop improved and more uniform services for early intervention in schizophrenia.

Feinstein Institutes associate professor Dr Robinson said: “With this new clinical research, we aim to improve treatment strategies and medication adherence and help patients continue to receive the care they need to get back to their everyday lives.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

With the help of ESPRITO programme, 11 clinics across four states will provide the NAVIGATE model of coordinated speciality care. The application of standard measurement and data gathering will help in providing enhanced treatment quality, consistency, and response.

The NIMH-funded clinical research will enable researchers to address hurdles in early-phase intervention and reduce hospitalisations, preventing patients from discontinuing the clinical study phase and improving overall outcomes.

Feinstein Institutes president and CEO Kevin Tracey said: “NIH support of early-phase schizophrenia research is in the national interest.

“Doctors Kane and Robinson’s research offers hope for patients to achieve a better quality of life.”

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact